Literature DB >> 8649767

Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics.

J Momand1, G P Zambetti.   

Abstract

A critical parameter affecting cell growth properties is the relative levels of the p53 tumor suppressor protein and the mdm-2 oncoprotein. Because mdm-2 overexpression is observed in several types of human cancers and its physical association with p53 appears essential for down-regulating p53 activity the proportion of p53 bound to mdm-2 was examined in four types of cells with divergent growth properties: (1) Growth arrested cells (Al) expressing high levels of wild-type p53 activity; (2) Tumorigenic cells (3T3DM) expressing high levels of mdm-2; (3) Immortalized non tumorigenic cells (Swiss3T3 and Balb/c3T3); and (4) Normal murine fibroblasts. In Al cells, greater than 78% of the p53 was not bound to mdm-2, demonstrating that excess free p53 is available for cell cycle arrest. In 3T3DM cells 100% of the p53 was bound to mdm-2 and these cells were unable to support p53-mediated transactivation, a p53 function essential for cell growth inhibition. In Swiss3T3 cells 75% of the p53 was bound to mdm-2. In Balb/c3T3 cells and normal cells no detectable mdm-2 was bound to p53. Since free p53 was detected in several of these cell lines the possibility that mdm-2 is completely titrated by p53 was investigated. However, free mdm-2 was present in all these cells. Phosphorylation of p53 does not appear to control complex formation since the free and the mdm-2-bound form of p53 from Al cells had identical phosphorylation maps. These data suggest that a high proportion of p53 bound to mdm-2 is observed in some cells with a more transformed phenotype and that p53-mdm-2 complex formation is controlled by a posttranslational event other than p53 phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649767

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

Review 1.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

2.  Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.

Authors:  J Roth; M Dobbelstein; D A Freedman; T Shenk; A J Levine
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

3.  c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation.

Authors:  David L Waning; Jason A Lehman; Christopher N Batuello; Lindsey D Mayo
Journal:  J Biol Chem       Date:  2010-11-16       Impact factor: 5.157

4.  Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis.

Authors:  A Leri; Y Liu; P P Claudio; J Kajstura; X Wang; S Wang; P Kang; A Malhotra; P Anversa
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

5.  Expression of mdm2 and p53 in epithelial neoplasms of the colorectum.

Authors:  X P Hao; T Günther; A Roessner; A B Price; I C Talbot
Journal:  Mol Pathol       Date:  1998-02

6.  Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.

Authors:  V G Gorgoulis; P Zacharatos; A Kotsinas; T Liloglou; A Kyroudi; M Veslemes; A Rassidakis; T D Halazonetis; J K Field; C Kittas
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

7.  Therapeutic considerations for Mdm2: not just a one trick pony.

Authors:  Jason A Lehman; Jacob A Eitel; Christopher N Batuello; Lindsey D Mayo
Journal:  Expert Opin Drug Discov       Date:  2008-11       Impact factor: 6.098

8.  Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation.

Authors:  Jonas A Nilsson; Kirsteen H Maclean; Ulrich B Keller; Helene Pendeville; Troy A Baudino; John L Cleveland
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.